UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 247

Sortiert nach

A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language model

PloS one, 2023-12, Vol.18 (12), p.e0294560-e0294560

2023

Volltextzugriff (PDF)

Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization

PloS one, 2020-06, Vol.15 (6), p.e0235048

2020

Volltextzugriff (PDF)

Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi)

Orphanet journal of rare diseases, 2022-02, Vol.17 (1), p.48-48, Article 48

2022

Volltextzugriff (PDF)

The effect of a pharmaceutical transitional care program on rehospitalisations in internal medicine patients: an interrupted-time-series study

BMC health services research, 2019-10, Vol.19 (1), p.717-717, Article 717

2019

Volltextzugriff (PDF)

Strategic recommendations from the STARS project to foster academic drug development

Nature reviews. Drug discovery, 2023-04, Vol.22 (4), p.251-252

2023

Volltextzugriff (PDF)

Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study

Drug safety, 2013-11, Vol.36 (11), p.1105-1115

2013

Volltextzugriff (PDF)

Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire

Drug safety, 2013-09, Vol.36 (9), p.765-777

2013

Volltextzugriff (PDF)

Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR

Drug safety, 2019-04, Vol.42 (4), p.477-489

2019

Volltextzugriff (PDF)

A Decade of Safety-Related Regulatory Action in the Netherlands: A Retrospective Analysis of Direct Healthcare Professional Communications from 1999 to 2009

Drug safety, 2010-06, Vol.33 (6), p.463-474

2010

Volltextzugriff (PDF)

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020

Clinical and translational science, 2023-11, Vol.16 (11), p.2394-2412

2023

Volltextzugriff (PDF)

Use of antibacterial fixed‐dose combinations in the private sector in eight Latin American Countries between 1999 and 2009

Tropical medicine & international health, 2013-04, Vol.18 (4), p.416-425

2013

Volltextzugriff (PDF)

Impact of Safety-Related Regulatory Action on Clinical Practice: A Systematic Review

Drug safety, 2012-05, Vol.35 (5), p.373-385

2012

Volltextzugriff (PDF)

Differences in medication beliefs between pregnant women using medication, or not, for chronic diseases: a cross-sectional, multinational, web-based study

BMJ open, 2020-02, Vol.10 (2), p.e034529-e034529

2020

Volltextzugriff (PDF)

Safety Communication Tools and Healthcare Professionals’ Awareness of Specific Drug Safety Issues in Europe: A Survey Study

Drug safety, 2018-07, Vol.41 (7), p.713-724

2018

Volltextzugriff (PDF)

Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment

Frontiers in pharmacology, 2019-09, Vol.10, p.1031-1031

2019

Volltextzugriff (PDF)

Registries supporting new drug applications

Pharmacoepidemiology and drug safety, 2017-12, Vol.26 (12), p.1451-1457

2017

Volltextzugriff (PDF)

Community Use of Repurposed Drugs Before and During COVID-19 Pandemic in the Netherlands: An Interrupted Time-Series Analysis

Clinical epidemiology, 2023-09, Vol.15, p.923-937

2023

Volltextzugriff (PDF)

Preventable and Non-Preventable Adverse Drug Events in Hospitalized Patients: A Prospective Chart Review in the Netherlands

Drug safety, 2011-11, Vol.34 (11), p.1089-1100

2011

Volltextzugriff (PDF)

Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study

Frontiers in pharmacology, 2021-02, Vol.11, p.617409-617409

2021

Volltextzugriff (PDF)

Empirical management of community-acquired pneumonia: impact of concurrent A/H1N1 influenza pandemic on guideline implementation

Journal of antimicrobial chemotherapy, 2011-12, Vol.66 (12), p.2864-2871

2011

Volltextzugriff (PDF)

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe

Frontiers in pharmacology, 2021-04, Vol.12, p.626766-626766

2021

Volltextzugriff (PDF)

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making

Clinical pharmacology and therapeutics, 2023-01, Vol.113 (1), p.135-151

2023

Volltextzugriff (PDF)

Attention for sex in COVID-19 trials: a review of regulatory dossiers

BMJ global health, 2022-03, Vol.7 (3), p.e008173

2022

Volltextzugriff (PDF)

Improving compliance with hospital antibiotic guidelines: a time-series intervention analysis

Journal of antimicrobial chemotherapy, 2005-04, Vol.55 (4), p.550-557

2005

Volltextzugriff (PDF)

The influence that electronic prescribing has on medication errors and preventable adverse drug events: an interrupted time-series study

Journal of the American Medical Informatics Association : JAMIA, 2009-11, Vol.16 (6), p.816-825

2009

Volltextzugriff (PDF)

1 – 25 von 247

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(239)
Mit Volltextzugriff
(234)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(210)
Life Sciences & Biomedicine
(199)
Humans
(171)
Female
(105)
Male
(78)
Adult
(67)
Pharmacology & Pharmacy
(57)
Middle Aged
(55)
Biological And Medical Sciences
(52)
Obstetrics & Gynecology
(49)
Pregnancy
(49)
Medical Sciences
(48)
Medicine
(43)
Aged
(40)
Public, Environmental & Occupational Health
(40)
Reproductive Biology
(37)
Medicine & Public Health
(36)
Patients
(33)
Drug Safety And Pharmacovigilance
(29)
Pharmacology/toxicology
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language model

Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization

Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi)

The effect of a pharmaceutical transitional care program on rehospitalisations in internal medicine patients: an interrupted-time-series study

Strategic recommendations from the STARS project to foster academic drug development

Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study

Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire

Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR

A Decade of Safety-Related Regulatory Action in the Netherlands: A Retrospective Analysis of Direct Healthcare Professional Communications from 1999 to 2009

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020

Use of antibacterial fixed‐dose combinations in the private sector in eight Latin American Countries between 1999 and 2009

Impact of Safety-Related Regulatory Action on Clinical Practice: A Systematic Review

Differences in medication beliefs between pregnant women using medication, or not, for chronic diseases: a cross-sectional, multinational, web-based study

Safety Communication Tools and Healthcare Professionals’ Awareness of Specific Drug Safety Issues in Europe: A Survey Study

Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment

Registries supporting new drug applications

Community Use of Repurposed Drugs Before and During COVID-19 Pandemic in the Netherlands: An Interrupted Time-Series Analysis

Preventable and Non-Preventable Adverse Drug Events in Hospitalized Patients: A Prospective Chart Review in the Netherlands

Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study

Empirical management of community-acquired pneumonia: impact of concurrent A/H1N1 influenza pandemic on guideline implementation

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making

Attention for sex in COVID-19 trials: a review of regulatory dossiers

Improving compliance with hospital antibiotic guidelines: a time-series intervention analysis

The influence that electronic prescribing has on medication errors and preventable adverse drug events: an interrupted time-series study

Suchergebnisse filtern